| DB ID | MyCo_1603 |
| Title | Comparison of diagnostic efficacy of galactomannan lateral flow assay vs enzyme immunoassay: importance of storage conditions |
| Year | 2025 |
| PMID | 40305535 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | Approval for the research was granted by the Clinical Research Ethics Committee at Gaziantep University. The ethics committee approved the study on 23 February 2022, under decision number 2022/71. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Turkey |
| Cohort | A total of 192 patients who met the inclusion criteria were included in the study. |
| Cohort No. | 192 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis is life-threatening, particularly in critically ill patients and immunocompromised individuals, such as those with hematologic malignancies. It has a mortality rate of 50% even with treatment, which can rise to 99% if left untreated. Invasive aspergillosis is not a notifiable disease; therefore, determining its global burden is challenging. Data from over 120 countries indicate that more than 2.1 million people develop invasive aspergillosis each year, with a crude annual mortality rate of 85.2%. The incidence of invasive aspergillosis in patients with hematologic malignancies who develop neutropenia due to prolonged chemotherapy or undergo bone marrow transplantation typically ranges from 6% to 16%. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | GM ELISA Kit (Dynamiker® Biotechnology, Tianjin, China), |
| Assay Data | GM lateral flow assays (IMMY® Diagnostics, Oklahoma, USA) |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
